| RVTY |
Report |
Pro forma adjusted EPS |
BEAT |
pred ~$1.24 vs. cons $1.21 |
MEDIUM |
| RVTY |
Report |
Pro forma revenue |
IN-LINE |
pred ~$706M vs. cons $703M |
MEDIUM |
| RVTY |
Report |
Pro forma organic revenue growth |
BEAT |
pred ~3.2% vs. cons 2.5% |
MEDIUM |
| RVTY |
Guide |
FY2026 pro forma organic growth |
UNCHANGED |
guide ~3.5% vs. cons 3.5% (FY2026) |
MEDIUM |
| RVTY |
Guide |
FY2026 pro forma revenue |
UNCHANGED |
guide ~$2.825B vs. cons $2.825B (FY2026) |
MEDIUM |
| RVTY |
Guide |
FY2026 pro forma adjusted EPS |
UNCHANGED |
guide ~$5.25 vs. cons $5.26 (FY2026) |
MEDIUM |
| RVTY |
Guide |
FY2026 pro forma adjusted operating margin |
UNCHANGED |
guide ~28.4% vs. cons 28.4% (FY2026) |
HIGH |
| RVTY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
MEDIUM |
| RVTY |
Return |
5-day cumulative residual |
+1.0% (STABILIZE) |
A modest Q2 EPS/organic-growth beat should support an initial ~2.0% residual move, but unchanged FY2026 revenue, EPS, growth, and margin guidance leaves out-period estimates near ~$5.25 versus ~$5.26 consensus; absent a guide raise, revisions should be limited and the initial reaction should stabilize toward ~1.0% by day five. |
MEDIUM |